



(11) **EP 3 446 712 A8**

(12) **CORRECTED EUROPEAN PATENT APPLICATION**

(15) Correction information:
Corrected version no 1 (W1 A1)
Corrections, see
Bibliography INID code(s) 71

(51) Int Cl.:
A61K 47/00 ^(2006.01) **A61K 31/7105** ^(2006.01)

(48) Corrigendum issued on:
10.04.2019 Bulletin 2019/15

(43) Date of publication:
27.02.2019 Bulletin 2019/09

(21) Application number: **18185286.4**

(22) Date of filing: **14.03.2014**

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME

(30) Priority: **14.03.2013 US 201361783663 P**

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
14718284.4 / 2 968 586

(71) Applicants:
• **Translate Bio, Inc.**
Lexington, MA 02421 (US)
• **Ethis GmbH**
82152 Planegg (DE)

(72) Inventors:
• **HEARTLEIN, Michael**
Lexington, MA 02421 (US)

- **GUILD, Braydon Charles**
Concord, MA 01742 (US)
- **DEROSA, Frank**
Lexington, MA 02421 (US)
- **RUDOLPH, Carsten**
82152 Krailing (DE)
- **PLANK, Christian**
82234 Wessling (DE)
- **SMITH, Lianne**
Lexington, MA 02421 (US)

(74) Representative: **Goodfellow, Hugh Robin**
Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA (GB)

Remarks:

This application was filed on 24-07-2018 as a
divisional application to the application mentioned
under INID code 62.

(54) **CFTR MRNA COMPOSITIONS AND RELATED METHODS AND USES**

(57) Materials, formulations, production methods,
and methods for delivery of CFTR mRNA for induction
of CFTR expression, including in the mammalian lung

are provided. The present invention is particularly useful
for treating cystic fibrosis.

EP 3 446 712 A8